ArticleCancer medicine2026
Prognostic Impact of Arterial Phase Hyperenhancement After Proton Beam Therapy for Untreated Solitary Hepatocellular Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the significance of persistent arterial-phase hyperenhancement (APHE) on contrast-enhanced CT/MRI at 6 and 12 months after proton beam therapy (PBT) for hepatocellular carcinoma (HCC).
methodsWe retrospectively analyzed 108 patients with solitary HCC without vascular invasion who underwent definitive PBT as initial treatment between January 2008 and December 2020. APHE was assessed on contrast-enhanced CT/MRI at approximately 6 and 12 months. Overall survival (OS), local control (LC), and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Associations between APHE and outcomes were evaluated using landmark analyses and Cox models.
resultsThe median follow-up time was 4.64 years. APHE assessment was available in 87 patients at 6 months and 89 patients at 12 months; APHE was observed in 28 (32.2%) and 26 (29.2%), respectively. At the 6-month landmark, APHE was associated with worse subsequent OS and PFS, whereas LC did not differ significantly. At the 12-month landmark, APHE was associated with worse subsequent LC and PFS and borderline worse OS. The 3-year LC and PFS rates from the 12-month landmark were 69.1% and 25.3% in patients with APHE versus 89.6% and 54.3% in those without APHE (LC: p = 0.015; PFS: p = 0.025). However, after adjustment for clinical and treatment-related factors, APHE status was not independently associated with OS, LC, or PFS in the multivariate landmark analyses.
conclusionPersistent intratumoral APHE at 12 months after PBT was associated with an increased subsequent risk of local failure in landmark analysis, but was not an independent prognostic factor. Persistent APHE may warrant careful imaging follow-up and clinical reassessment but should not be regarded as definitive evidence of viable tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.